Trials of investigative treatments for cystic fibrosis from Vertex Pharmaceuticals have found improved outcomes for patients who do not respond to current treatments through the addition of three different compounds to regimens of ivacaftor and tezacaftor. Vertex may choose one triple-combo this year to advance to late-stage trials next year.
Tokyo-based PeptiDream agreed to work with Kleo Pharmaceuticals on the development of immuno-oncology drugs for multiple indications using PeptiDream's Peptide Discovery Platform System technology to identify peptides against targets selected by Kleo. Under the deal, Kleo will get an upfront payment and retain rights to develop and market products resulting from the agreement, while PeptiDream will receive a tiered portion of the proceeds.
Mallinckrodt, which is said by US authorities to be one of the largest makers of generic oxycodone, agreed to pay $35 million to resolve allegations that it violated provisions of the Controlled Substances Act when it failed to discover suspicious orders of controlled substances and notify the US Drug Enforcement Administration. The DEA said Mallinckrodt's alleged failure to follow record-keeping requirements at its Hobart, N.Y., plant caused discrepancies between the number of tablets manufactured and the number reported, although the company denies the allegations and says the "settlement contains no admission of liability for civil penalties for relevant conduct."
Drugmakers are starting to take responsibility and work with pharmacy benefit managers to make their products more affordable, says Express Scripts Chief Medical Officer Steve Miller. The prices on three new drugs were lower than expected, and Miller says there is "recognition by certain pharmaceutical manufacturers that they are in control of their price and can do something."
Gilead Sciences' single-tablet Vosevi, or sofosbuvir 400 mg/velpatasvir 100 mg/voxilaprevir 100 mg, has been approved by the FDA as a treatment for adult patients with chronic hepatitis C virus with genotypes 1 through 6 who had prior treatment with a regimen containing an NS5A inhibitor. The drug is also approved for HCV patients with genotype 1a or 3 who were previously treated with a regimen containing sofosbuvir without an NS5A inhibitor.
A private placement brought in $18.2 million for Uni-Bio Science Group, which recently launched the insulin secretagogue Bokangtai, or mitiglinide, a generic version of Kissei Pharmaceutical's Glufast.
Aon plans to announce second-quarter and full-year 2017 results on Friday, Aug. 4, in a news release to be issued before the market opens. Greg Case, president and CEO, will host a conference call at 7:30 a.m. Central time on Aug 4. Read more.
There's no better time to get something than at exactly the moment you need it. The rapid growth of the "on-demand" economy, where goods and services are ordered online and delivered promptly, has meant a new way of doing business -- and working. How are businesses harnessing this on-demand talent? Learn more.
There is no end. There is no beginning. There is only the infinite passion of life.
Aon provides Life Sciences companies with end-to-end risk solutions, supporting organizations from the initial discovery phase to final product launch. The practice provides solutions across the Life Sciences for pharmaceutical manufacturers; generic and OTC pharmaceutical companies; biotechnology and biopharmaceutical companies; genomic and proteomic companies; drug delivery system; diagnostic substance companies; and medical device and equipment manufacturers.
Aon plc (NYSE:AON) is a leading global professional services firm providing a broad range of risk, retirement and health solutions. Our 50,000 colleagues in 120 countries empower results for clients by using proprietary data and analytics to deliver insights that reduce volatility and improve performance.